|Source||Humanized (from mouse)|
cBR96-doxorubicin immunoconjugate (BMS-182248/SGN-15) was an antibody-drug conjugate (ADC) directed to the Lewis-Y antigen designed for the treatment of cancer. The payload was doxorubicin which was connected with a hydrazone linker to cysteine residues of the Lewis-Y specific monoclonal antibody BR96. Clinical development of cBR96-doxorubicin immunoconjugate was discontinued.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|